Stock GKOS GLAUKOS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Company Glaukos Corporation

Equities

GKOS

US3773221029

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 04:00:01 2024-04-25 pm EDT 		5-day change 1st Jan Change
100.1 USD -0.81% Intraday chart for Glaukos Corporation +5.23% +25.94%
Apr. 11 Mizuho Securities Adjusts Price Target on Glaukos to $100 From $85, Maintains Neutral Rating MT
Apr. 11 Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing MT

Business Summary

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Number of employees: 907

Sales per Business

USD in Million2022Weight2023Weight Delta
Glaucoma
75.3 %
214 75.7 % 237 75.3 % +10.64%
Corneal Health
24.7 %
69 24.3 % 78 24.7 % +13.18%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
69.7 %
203 71.9 % 219 69.7 % +7.95%
International
30.3 %
80 28.1 % 95 30.3 % +19.71%

Managers

Managers TitleAgeSince
Thomas Burns CEO
 Chief Executive Officer 63 00-12-31
Alex Thurman DFI
 Director of Finance/CFO 54 16-06-30
Joseph Gilliam PSD
 President 48 17-05-04
Jay L. Katz CTO
 Chief Tech/Sci/R&D Officer - 17-02-21
Chris Lewis IRC
 Investor Relations Contact - -
Diane Biagianti PRN
 Corporate Officer/Principal 61 20-05-31
Gabriella Szekely PRN
 Corporate Officer/Principal - 14-12-31
Michele M. Allegretto HRO
 Human Resources Officer - 15-04-30
Tomas Navratil PRN
 Corporate Officer/Principal 47 20-09-30
David S. Haffner PRN
 Corporate Officer/Principal - 01-01-31

Members of the board

Members of the board TitleAgeSince
Gilbert Kliman BRD
 Director/Board Member 65 06-12-31
David Hoffmeister BRD
 Director/Board Member 69 14-06-30
Aimee Weisner BRD
 Director/Board Member 55 14-06-30
Mark Foley BRD
 Director/Board Member 58 14-06-30
Thomas Burns CEO
 Chief Executive Officer 63 00-12-31
Marc Stapley BRD
 Director/Board Member 54 14-06-30
Denice Torres BRD
 Director/Board Member 64 21-02-28
Leana Wen BRD
 Director/Board Member 41 21-02-28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 50,004,696 48,224,384 ( 96.44 %) 28,000 ( 0.0560 %) 96.44 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
15.19 %
7,514,575 15.19 % 709 M $
Fidelity Management & Research Co. LLC
11.76 %
5,819,110 11.76 % 549 M $
Vanguard Fiduciary Trust Co.
10.59 %
5,236,738 10.59 % 494 M $
Brown Capital Management LLC
5.453 %
2,697,794 5.453 % 254 M $
STATE STREET CORPORATION
3.673 %
1,816,911 3.673 % 171 M $
Weatherbie Capital LLC
3.325 %
1,645,081 3.325 % 155 M $
Janus Henderson Investors US LLC
3.268 %
1,616,534 3.268 % 152 M $
Invesco Advisers, Inc.
3.179 %
1,572,615 3.179 % 148 M $
Thomas Burns
3.101 %
1,534,312 3.101 % 145 M $
Wellington Management Co. LLP
2.710 %
1,340,500 2.710 % 126 M $

Company contact information

Glaukos Corp.

One Glaukos Way

92656, Aliso Viejo

+949 367 9600

http://www.glaukos.com
address Glaukos Corporation(GKOS)

Sector

Healthcare
Healthcare Services
Healthcare Equipment & Supplies
Medical Equipment, Supplies & Distribution
Medical Devices & Implants

Sales per Business

Sales per region

Ratings for Glaukos Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
100.1 USD
Average target price
106.6 USD
Spread / Average Target
+6.53%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

1st Jan change Capi.
GLAUKOS CORPORATION Stock Glaukos Corporation
+25.94% 5.02B
STRYKER CORPORATION Stock Stryker Corporation
+12.59% 128B
SMITH & NEPHEW PLC Stock Smith & Nephew Plc
-10.58% 10.51B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD. Stock Imeik Technology Development Co.,Ltd.
-0.39% 8.71B
INSPIRE MEDICAL SYSTEMS, INC. Stock Inspire Medical Systems, Inc.
+13.56% 7B
AXONICS, INC. Stock Axonics, Inc.
+6.93% 3.39B
ENOVIS CORPORATION Stock Enovis Corporation
-1.64% 3.02B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Balance Medical Technology Co.,Ltd.
-11.96% 2.07B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. Stock Shanghai MicroPort Endovascular MedTech Co., Ltd.
-7.25% 2.06B
DOUBLE MEDICAL TECHNOLOGY INC. Stock Double Medical Technology Inc.
-25.23% 1.73B
Medical Devices & Implants
  1. Stock Market
  2. Equities
  3. GKOS Stock
  4. Company Glaukos Corporation